- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00579046
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease (ELAB)
Erythropoietin Treatment of Anemia Complicating Chronic Obstructive Pulmonary Disease: Functional Impact During Exertion
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The development of anemia in patients with chronic obstructive pulmonary disease (COPD) is now taken as a predictor of increased morbidity and mortality. Preliminary data from patients investigated in our department indicate a negative correlation between anemia severity and 6-minute walking distance. Our working hypothesis is that hemoglobin level correction by erythropoietin therapy will improve the effort capacity of patients with COPD and anemia. Our objective is to conduct a pilot study of the efficacy of darbepoetin alfa.
The study will include about 15 patients with COPD recruited at three pulmonology centers based on two selection criteria: COPD stage II or III or IV according to GOLD criteria and hemoglobin level less than 12 g/dL. Effort capacity will be evaluated chiefly by performing a 6-minute walking test and by measuring VO2 at maximum exertion on a bicycle ergometer with increasing loads. Darbepoetin alfa will be given for 2 months. If the hemoglobin increase is less than 1 g/dL after 1 month, the dosage will be increased by 25%.
Effort parameters will be measured at baseline and after 1 and 2 months of treatment. Among secondary objectives, we will evaluate functional ergospirometric parameters and laboratory tests for inflammation. Total study duration will not exceed 18 months.
Type d'étude
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Creteil, France, 94 000
- CHU Henri Mondor
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male and female aged 40-75 years
- Diagnosis of a moderate to very severe COPD (stage II, III or IV according to GOLD criteria)
- A ratio of post-bronchodilator FEV1 to forced vital capacity (FVC) < 70%
- A FEV1 < 80% of the predicted value
- Hemoglobin level less than 12 g/dL
- Peak VO2 less than 80% of predict value and 6-min walk test distance less than 500 meters
Exclusion Criteria:
- Hemorrhagic anemia
- Iron deficiency anemia (ferritin < 30 ng/ml)
- Folate and Vitamin B12 deficiency anemia
- Myelodysplastic Syndrome
- Chronic disease associated with anemia: renal insufficiency, inflammatory disease, neoplastic disease, left ventricular insufficiency (ejection fraction < 40%)
- Chronic disease likely to interfere with dyspnea or exercise testing (cardiac insufficiency, neurologic disease, claudication)
- Acute exacerbation of COPD within the last 4 weeks
- History of thromboembolic disease
- Contraindications for cardiopulmonary exercise testing
- Contraindications for darbepoetin alfa treatment: uncontrolled arterial hypertension or hypersensitivity reaction to darbepoetin alfa
- Pregnancy or breast-feeding (women of reproductive potential should use adequate birth control measures during the whole duration of study treatment)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 1
|
Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml). Frequency: every week for 2 months: 8 injections |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Measure: 6-minute walk distance
Délai: before treatment; at one month and two months of treatment
|
before treatment; at one month and two months of treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
VO2 max
Délai: before treatment; at one month and two months
|
before treatment; at one month and two months
|
MRC Dyspnea score
Délai: before treatment; at one month and two months
|
before treatment; at one month and two months
|
St. George quality of life score
Délai: before treatment and at two months of treatment
|
before treatment and at two months of treatment
|
Inflammation biological parameters
Délai: before treatment and at two months of treatment
|
before treatment and at two months of treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Laurent Savale, MD, Assistance Publique - Hôpitaux de Paris
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P 061011
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Darbepoetin alfa
-
AmgenComplété
-
Imperial College LondonRecrutementEncéphalopathie néonataleRoyaume-Uni
-
AmgenComplétéSyndromes myélodysplasiques
-
AmgenComplétéMaladie rénale chronique | Maladie du rein
-
Herning HospitalAmgenComplétéCancer colorectalDanemark
-
AmgenComplété
-
AmgenComplétéCancer du sein | Anémie